Pandemic Impact Limited As Chugai Reports Strong First Half
But Outlook More Uncertain
Roche’s Japanese affiliate says the impact of the pandemic on its second quarter was limited, but points to a more uncertain outlook for the rest of the year, during which it vows to keep focusing on innovation.
You may also be interested in...
Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints.
Tiragolumab plus Tecentriq increased response rates versus Tecentriq alone in a Phase II study, with the greatest benefit in PD-L1-high NSCLC. The combination regimen already is being test in Phase III.
Coronavirus Update: Rapid Japan Approval For Remdesivir, Combination With Lilly's Olumiant Is Next Hope
Plus: Chugai enters into Singapore research alliance, Korean consortium reports vaccine progress.